Kenvue (NYSE:KVUE - Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.100-1.200 for the period, compared to the consensus EPS estimate of 1.140. The company issued revenue guidance of $15.6 billion-$15.9 billion, compared to the consensus revenue estimate of $15.6 billion.
Analyst Ratings Changes
A number of research analysts recently weighed in on KVUE shares. The Goldman Sachs Group assumed coverage on Kenvue in a research report on Friday, March 1st. They set a neutral rating and a $20.00 price objective for the company. Sanford C. Bernstein initiated coverage on Kenvue in a research report on Thursday, April 11th. They issued an underperform rating and a $18.00 price target for the company. Royal Bank of Canada cut their price objective on shares of Kenvue from $25.00 to $24.00 and set an outperform rating on the stock in a research report on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a market perform rating for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Kenvue from $25.00 to $24.00 and set an overweight rating on the stock in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and an average price target of $24.38.
Get Our Latest Report on Kenvue
Kenvue Stock Performance
NYSE:KVUE traded up $0.37 on Wednesday, hitting $20.45. The stock had a trading volume of 23,642,579 shares, compared to its average volume of 17,121,814. The business's 50-day simple moving average is $19.87 and its two-hundred day simple moving average is $20.12. Kenvue has a 52-week low of $17.82 and a 52-week high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The company had revenue of $2.89 billion during the quarter, compared to analyst estimates of $3.79 billion. The firm's revenue for the quarter was down 24.9% compared to the same quarter last year. Sell-side analysts predict that Kenvue will post 1.15 earnings per share for the current year.
Kenvue Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 annualized dividend and a yield of 3.91%.
About Kenvue
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
